Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
The present invention provides heteroaryl ketone fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
1. The compound (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5, 6,7, 8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, having the formula:
2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
3. A method of modulating a glucocorticoid receptor, comprising contacting a glucocorticoid receptor with a compound having the formula:
thereby modulating the glucocorticoid receptor.
4. The compound (R)-(1-(4-fluorophenyl)-6-4-(trifluoromethyl)phenyl)sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone, wherein said compound has the formula:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 , wherein said compound has the formula:
6. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound, or a pharmaceutically acceptable salt of said compound, wherein said compound has the formula:
7. A method of modulating a glucocorticoid receptor, comprising contacting a glucocorticoid receptor with a compound, or a pharmaceutically acceptable salt of said compound, wherein said compound has the formula:
thereby modulating the glucocorticoid receptor.
8. The compound (R)-(1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone, having the formula:
9. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
10. A method of modulating a glucocorticoid receptor, comprising contacting a glucocorticoid receptor with a compound having the formula:
thereby modulating the glucocorticoid receptor.